Skip to main content

Table 5 Efficacy analysis

From: Safety and efficacy of Rapamune® (Sirolimus) in kidney transplant recipients: results of a prospective post-marketing surveillance study in Korea

 

Total (N = 209)

Yes, n (%)

95% CI (lower, upper)

Total, n (%)

Acute rejection

6 (2.87)

0.91, 5.79

209 (100.00)

Patient survivala

205 (99.51)

98.57, 100.00

206 (98.56)

Graft survivala

205 (99.51)

98.57, 100.00

206 (98.56)

Graft functionb

  

 eGFR (mL/min)

64.72 ± 19.56c

182 (87.08)

  1. Abbreviations: CI confidence interval, eGFR estimated glomerular filtration rate
  2. aData were not available for 3 subjects due to loss of follow-up
  3. bData were not available for 27 subjects
  4. ceGFR is expressed as a mean ± standard deviation
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us